New Data on Teva's Copaxone and Laquinimod to Be Highlighted at ECTRIMS/ACTRIMS

Teva Pharmaceutical Industries Ltd. TEVA today announced that more than 30 scientific presentations on the company's multiple sclerosis portfolio, including the market-leading treatment Copaxone® and the late-stage oral therapy laquinimod, will be featured during the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS AND ACTRIMS). This year's meeting, recognized as the world's largest annual international conference focused on MS research, will be held in Amsterdam, The Netherlands, October 19-22, 2011. Select data highlights include: Late-breaking presentation of data from the BRAVO study, the second global Phase III clinical trial evaluating oral laquinimod for the treatment of MS. Additional data from the ALLEGRO study demonstrating the positive impact of laquinimod on disability accumulation and rate of severe relapses, as well as patient-reported outcomes. Preclinical research further illuminating the novel neuroprotective mechanism of action (MOA) of laquinimod and its direct effect in the central nervous system. Study results from trials designed to determine the neuroprotective effects of treatment with COPAXONE® (glatiramer acetate injection) in two different experimental autoimmune encephalomyelitis models. Additional preclinical data examining the anti-inflammatory mechanism of COPAXONE®. Data illustrating characteristics of the patient population examined in the Therapy Optimization in Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study conducted in MS examining self-reported patient outcomes to medication therapy management via specialty pharmacy programs. The TOP MS study was designed to evaluate the benefits of adherence to therapy on MS patients' health outcomes.